MHC Class II Expression and Tumor Immunity Dynamics

The expression of Major Histocompatibility Complex class II (MHC II) molecules on tumour cells has emerged as a critical determinant of antitumour immunity. Conventionally restricted to professional antigen-presenting cells, aberrant tumoral MHC II expression is driven by inflammatory cues such as interferon-gamma and orchestrated by the master regulator CIITA. Surface display of MHC II-bound peptides enables direct engagement of CD4+ T helper cells, which in turn coordinate cytotoxic CD8+ T-cell activation, promote dendritic cell maturation and reshape the tumour microenvironment. Dynamic regulation of this pathway influences tumour infiltration by lymphocytes, the formation of tertiary lymphoid structures and the balance between effector and regulatory immune subsets. Clinically, MHC II status on malignant cells has been linked to patient prognosis, response to immune checkpoint inhibitors and may inform vaccine strategies that harness CD4+ T helper cell help. Understanding the molecular controls and functional consequences of tumoral MHC II presentation is pivotal for biomarker development, patient stratification and the design of next-generation immunotherapies.

Research from Nature Portfolio

Recent studies have delineated the role of tumour cell MHC class II expression as an intrinsic tumour phenotype predictive of response to immune checkpoint blockade. Analysis across melanoma cell lines revealed a subset characterised by constitutive or cytokine-inducible MHC class II expression, accompanied by transcriptional programmes related to T-cell receptor signalling and allograft rejection. Clinical correlation demonstrated that patients with MHC class II-positive tumours experienced enhanced progression-free and overall survival following anti-PD-1 therapy, with enriched CD4+ and CD8+ T-cell infiltration. Methodologies included immunohistochemical detection of HLA-DR to stratify patient cohorts, offering a tangible biomarker for refining immunotherapy selection.

MHC Class II Expression and Tumor Immunity Dynamics publication trend

The graph below shows the total number of articles in mhc class ii expression and tumor immunity dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

MHC class II: Cell-surface molecules that present extracellular antigens to CD4+ T cells.

HLA-DR: A human MHC class II isotype central to antigen presentation.

CIITA: Master transcriptional regulator of MHC class II gene expression.

CD4+ T helper cell: Lymphocyte subset that orchestrates adaptive immune responses.

Immune checkpoint inhibitor: Therapeutic agent that blocks inhibitory pathways to enhance T-cell activity.

Tumour-infiltrating lymphocyte (TIL): T cell that has migrated into a tumour microenvironment.

References

1. HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker. Frontiers in Immunology (2024).
2. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nature Communications (2016).
3. Characterising the prognostic potential of HLA-DR during colorectal cancer development. Cancer Immunology, Immunotherapy (2020).
4. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine. Frontiers in Immunology (2019).